LexDanaLexDanabeta
Inventor

ROBERT S. KANIA

Inventor
US

Overview

5→
Patents
2023–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 5 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
C07DHeterocyclic compounds27%
A61KPreparations for medical, dental or toiletry purposes18%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium18%
PatentTitleYear
12,595,245Inhibitors of MET kinase202612,122,800Inhibitors of MEK kinase202411,814,384Inhibtors of Raf kinases202311,780,862Inhibitors of MEK kinase202311,753,395Inhibitors of MET kinase2023

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2023–2024Patents assigned to KINNATE BIOPHARMA INC (4)· patent assignee history
2023–2026Based in US· patent location history
2026Patents assigned to CELYN THERAPEUTICS INC (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
KINNATE BIOPHARMA INC42023–2024
CELYN THERAPEUTICS INC12026
Locations
LocationPatentsSpan
US52023–2026